Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sam D Sanderson

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Expert Opinion on Biological Therapy|March 21, 2008
Vaccines to combat smokingRick A Bevins, Jamie L Wilkinson, Sam D Sanderson
International Immunopharmacology|April 30, 2008
A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cellsGanapati V Hegde, Erin Meyers-Clark, Shantaram S Joshi, et al.
International Immunopharmacology|May 27, 2014
Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthmaElizabeth B Staab, Sam D Sanderson, Sandra M Wells, et al.
Vaccine|October 23, 2010
A novel adjuvant for vaccine development in the agedEdward L Morgan, Marilyn L Thoman, Sam D Sanderson, et al.
Molecular Cancer Therapeutics|January 30, 2004
Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptidesTakashi Kurizaki, Michio Abe, Sam D Sanderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 2013
Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infectionsMark L Hanke, Cortney E Heim, Amanda Angle, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 30, 2002
Protein kinase C-alpha mediates cigarette smoke extract- and complement factor 5a-stimulated interleukin-8 release in human bronchial epithelial cellsRavindra Kashyap, Anthony A Floreani, Arthur J Heires, et al.
Vaccine|July 5, 2011
Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine modelGayathri Kollessery, Tara M Nordgren, Amit K Mittal, et al.
Clinical Immunology (Orlando, Fla.)|June 27, 2015
Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvantBala Vamsi K Karuturi, Shailendra B Tallapaka, Joy A Phillips, et al.
Vaccine|May 12, 2012
An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infectionChiung-Yu Hung, Brady J Hurtgen, Michael Bellecourt, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Expert Opinion on Biological Therapy|March 21, 2008
Vaccines to combat smokingRick A Bevins, Jamie L Wilkinson, Sam D Sanderson
International Immunopharmacology|April 30, 2008
A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cellsGanapati V Hegde, Erin Meyers-Clark, Shantaram S Joshi, et al.
International Immunopharmacology|May 27, 2014
Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthmaElizabeth B Staab, Sam D Sanderson, Sandra M Wells, et al.
Vaccine|October 23, 2010
A novel adjuvant for vaccine development in the agedEdward L Morgan, Marilyn L Thoman, Sam D Sanderson, et al.
Molecular Cancer Therapeutics|January 30, 2004
Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptidesTakashi Kurizaki, Michio Abe, Sam D Sanderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 2013
Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infectionsMark L Hanke, Cortney E Heim, Amanda Angle, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|January 30, 2002
Protein kinase C-alpha mediates cigarette smoke extract- and complement factor 5a-stimulated interleukin-8 release in human bronchial epithelial cellsRavindra Kashyap, Anthony A Floreani, Arthur J Heires, et al.
Vaccine|July 5, 2011
Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine modelGayathri Kollessery, Tara M Nordgren, Amit K Mittal, et al.
Clinical Immunology (Orlando, Fla.)|June 27, 2015
Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvantBala Vamsi K Karuturi, Shailendra B Tallapaka, Joy A Phillips, et al.
Vaccine|May 12, 2012
An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infectionChiung-Yu Hung, Brady J Hurtgen, Michael Bellecourt, et al.
Pageof 3